RNXT RenovoRx, Inc.
Price Chart
Executive Summary
RenovoRx reported $1.1 million in revenue for 2025, its first full year of commercialization, up from $43,000 in 2024, driven by early adoption of its RenovoCath device at U.S. cancer centers. The company raised $9.2 million in net proceeds, bringing cash on hand to $13 million, and advanced its Phase III TIGeR-PaC trial, which is on track for final data in 2027. Despite growing revenue, the net loss widened to $11.2 million.
Key Financial Metrics
Actionable Insight
The significant revenue growth from commercialization is positive, but the widening loss and long timeline to TIGeR-PaC data (2027) suggest cash burn will continue. The $13 million cash runway appears sufficient, but investors should monitor commercial growth rate and trial enrollment progress as near-term catalysts.
Key Facts
- 2025 revenue was $1.1 million (up from $43,000 in 2024), marking first full year of RenovoCath commercialization.
- Net loss increased to $11.2 million in 2025 from $8.8 million in 2024.
- Company raised $9.2 million in net proceeds via private placement, bringing total cash to $13 million as of March 2026.
- Phase III TIGeR-PaC trial has randomized 104 of 114 required patients; final data expected in 2027.
- 12 U.S. cancer centers are actively using RenovoCath, with 21 additional centers in evaluation or activation pipeline.
Financial Impact
Revenue grew over 2,500% YoY to $1.1 million, but operating losses expanded due to higher SG&A and R&D spending. $13 million in cash supports operations into 2027.
Risk Factors
- Long path to profitability given current burn rate and 2027 data readout timeline.
- Commercial adoption remains limited to 12 active centers; scalability of sales model is unproven.
- No revenue guidance provided for 2026, leaving growth expectations uncertain.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3265014 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 26, 2026
19d ago
|
Press Release
| $0.9160 $0.9210 | ▲ +0.55% | ▼ −0.54% | $0.8440 (−7.86%) |
|
May 19, 2026
26d ago
|
Press Release
| $0.8060 $0.9052 | ▲ +12.31% | ▲ +10.06% | $0.8440 (+4.71%) |
|
May 15, 2026
4w ago
|
10-K/A
| $0.7830 $0.9160 | ▲ +16.99% | ▲ +15.37% | $0.8440 (+7.79%) |
|
May 14, 2026
4w ago
|
8-K
| $0.8200 $0.8820 | ▲ +7.56% | ▲ +6.60% | $0.8440 (+2.93%) |
|
Apr 29, 2026
6w ago
|
Press Release
| $0.8310 $0.9280 | ▲ +11.67% | ▲ +8.56% | $0.8440 (+1.56%) |
|
Apr 28, 2026
6w ago
|
EFFECT
| $0.8400 $0.9280 | ▲ +10.48% | ▲ +8.78% | $0.8440 (+0.48%) |
|
Apr 16, 2026
8w ago
|
S-3
| $1.00 $0.8570 | ▼ −14.30% | ▼ −14.85% | $0.8440 (−15.60%) |
|
Apr 14, 2026
8w ago
|
Press Release
| $1.03 $0.9490 | ▼ −7.86% | ▼ −9.26% | $0.8440 (−18.06%) |
|
Mar 30, 2026
10w ago
|
8-K
| $1.01 $0.9390 | ▼ −7.03% | ▼ −10.97% | $0.8440 (−16.44%) |
|
Mar 30, 2026
10w ago
|
Press Release
| $1.01 $0.9390 | ▼ −7.03% | ▼ −10.97% | $0.8440 (−16.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access